Company Profile

Galileo Pharmaceuticals Inc (AKA: Galileo Laboratories Inc)
Profile last edited on: 7/27/2018      CAGE: 33VH8      UEI:

Business Identifier: Small molecule therapeutics to treat metabolic diseases
Year Founded
1993
First Award
2005
Latest Award
2005
Program Status
Inactive
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

5301 Patrick Henry Drive
Santa Clara, CA 95054
   (408) 654-5830
   N/A
   N/A
Location: Single
Congr. District: 17
County: Santa Clara

Public Profile

Initially doing business a Galileo Laboratories and organized around evidence-based nutraceuticals and pharmaceuticals, the firm was renamed Galileo Pharmaceuticals, Inc., with a flcous shifted to the discovery and development of therapeutics targeting redox signaling metabolic pathways. The company is developing a pipeline of treatments for diabetes and arthritis. Principals of Galileo are relocated to other concerns but with no clear indication of what happened to the firm itself

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
50-74
Revenue Range
5M-7.5M
VC funded?
Yes
Public/Private
Privately Held
Stock Info
----
IP Holdings
10-14

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2005 1 Army $69,871
Project Title: Metabolic Engineering for Performance Enhancement

Key People / Management

  Sekhar Boddupalli -- Vice President Discovery

  Daniel Chu -- Vice President, Medicinal Chemistry

  Julie Dove -- Director Finance & Accounting

  Charles E Hart

  David Liebowitz -- Executive Vice President R&D & CSO

  Gloria Pfister -- Senior Director Intellectual Property

Company News

There are no news available.